MA55978A - Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération - Google Patents
Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième générationInfo
- Publication number
- MA55978A MA55978A MA055978A MA55978A MA55978A MA 55978 A MA55978 A MA 55978A MA 055978 A MA055978 A MA 055978A MA 55978 A MA55978 A MA 55978A MA 55978 A MA55978 A MA 55978A
- Authority
- MA
- Morocco
- Prior art keywords
- egfr
- tyrosine kinase
- kinase inhibitors
- combination therapies
- bispecific anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847605P | 2019-05-14 | 2019-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55978A true MA55978A (fr) | 2022-03-23 |
Family
ID=78716450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055978A MA55978A (fr) | 2019-05-14 | 2020-05-14 | Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3968985A4 (fr) |
JP (1) | JP2022531980A (fr) |
KR (1) | KR20220010731A (fr) |
CN (1) | CN113840601A (fr) |
AU (1) | AU2020275272A1 (fr) |
BR (1) | BR112021022828A2 (fr) |
CA (1) | CA3140360A1 (fr) |
EA (1) | EA202193117A1 (fr) |
IL (1) | IL287962A (fr) |
MA (1) | MA55978A (fr) |
MX (1) | MX2021013955A (fr) |
SG (1) | SG11202112412QA (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CN102014913A (zh) * | 2008-03-06 | 2011-04-13 | 健泰科生物技术公司 | C-met和egfr拮抗剂的联合疗法 |
MX353144B (es) * | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
EP2922872B1 (fr) * | 2012-11-21 | 2018-10-10 | Janssen Biotech, Inc. | Anticorps egfr/c-met bispécifiques |
US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
-
2020
- 2020-05-14 JP JP2021567974A patent/JP2022531980A/ja active Pending
- 2020-05-14 EP EP20806609.2A patent/EP3968985A4/fr active Pending
- 2020-05-14 AU AU2020275272A patent/AU2020275272A1/en active Pending
- 2020-05-14 MA MA055978A patent/MA55978A/fr unknown
- 2020-05-14 CA CA3140360A patent/CA3140360A1/fr active Pending
- 2020-05-14 EA EA202193117A patent/EA202193117A1/ru unknown
- 2020-05-14 SG SG11202112412QA patent/SG11202112412QA/en unknown
- 2020-05-14 MX MX2021013955A patent/MX2021013955A/es unknown
- 2020-05-14 CN CN202080035662.6A patent/CN113840601A/zh active Pending
- 2020-05-14 KR KR1020217040739A patent/KR20220010731A/ko unknown
- 2020-05-14 BR BR112021022828A patent/BR112021022828A2/pt unknown
-
2021
- 2021-11-09 IL IL287962A patent/IL287962A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3968985A4 (fr) | 2023-07-26 |
CA3140360A1 (fr) | 2020-11-19 |
EP3968985A1 (fr) | 2022-03-23 |
EA202193117A1 (ru) | 2022-02-11 |
IL287962A (en) | 2022-01-01 |
CN113840601A (zh) | 2021-12-24 |
SG11202112412QA (en) | 2021-12-30 |
MX2021013955A (es) | 2022-03-11 |
BR112021022828A2 (pt) | 2022-04-12 |
AU2020275272A1 (en) | 2021-12-02 |
KR20220010731A (ko) | 2022-01-26 |
JP2022531980A (ja) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210304A1 (ar) | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث | |
IL267374B (en) | Imidazopyrazines as proton tyrosine kinase inhibitors | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
EA201591718A1 (ru) | Комбинации ингибиторов тирозинкиназы брутона и ингибиторов cyp3a4 | |
MA44146A (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
EA201990548A1 (ru) | Лечение кластерной головной боли | |
MA55089A (fr) | Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met | |
EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
MD3265084T2 (ro) | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
CL2013003133A1 (es) | Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa | |
MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
CO2019009586A2 (es) | Anticuerpos anti-gitr y métodos de uso de los mismos | |
MX2019005858A (es) | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo. | |
CL2021001432A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn | |
NZ733365A (en) | Dosage regimen for madcam antagonists | |
MA55818A (fr) | Anticorps et immunoconjugués de fr-alpha biparatopique | |
MA41948A (fr) | Procédés de traitement de patients présentant des mutations dans le domaine extracellulaire du récepteur de facteur de croissance épidermique (egfr) avec une combinaison de trois anticorps anti-egfr monoclonaux entièrement humains | |
MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
IL287745A (en) | Methods for the treatment of Sjögren's syndrome using Bruton's tyrosine kinase inhibitor | |
MA55558A (fr) | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs |